Regencell Bioscience Holdings Limited RGC PHARMA
Company Overview
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.32.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -49.18% |
| 6 Months: | -73.67% |
| 3 Months: | -68.12% |
| 1 Month: | +26.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)61.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RGC Regencell Bioscience Holdings Limited PHARMA | 6.82 | -682.00 | $3.37B | 0.00% | -57.45% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 7.62M | 6.27M | 4.74M | - |
| Operating Income | -7.62M | -6.27M | -4.74M | - |
| EBITDA | -7.01M | -5.50M | -3.99M | - |
| Interest Expense | - | - | - | - |
| Pretax Income | -7.59M | -6.06M | -4.36M | - |
| Tax Provision | 0 | 0 | 0 | - |
| Net Income | -7.45M | -5.87M | -4.30M | - |
| Diluted EPS | -0.02 | -0.01 | -0.01 | -0.01 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 |
|---|---|---|---|
| Total Assets | 18.02M | 12.62M | 8.44M |
| Current Assets | 16.44M | 11.62M | 8.11M |
| Cash & Equivalents | 6.42M | 1.56M | 2.96M |
| Inventory | - | - | - |
| Receivables | 27.60K | 56.55K | 152.78K |
| Total Liabilities | 938.03K | 632.32K | 219.51K |
| Current Liabilities | 577.76K | 606.91K | 193.58K |
| Long Term Debt | - | - | - |
| Total Debt | 771.25K | 463.67K | 85.74K |
| Total Equity | 17.07M | 12.03M | 8.22M |
| Shares Outstanding | 494.49M | 494.49M | 494.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 |
|---|---|---|---|
| Operating Cash Flow | -5.27M | -4.96M | -4.00M |
| Investing Cash Flow | -10.78M | 58.98K | 5.24M |
| Financing Cash Flow | 22.41M | 134.91K | 102.28K |
| Capital Expenditure | -780.88K | -27.39K | -5.38K |
| Free Cash Flow | -6.05M | -4.99M | -4.01M |
| Net Change in Cash | 6.36M | -4.77M | 1.34M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -43.6% | -48.8% | -52.3% | - |
| ROCE % | -43.7% | -52.2% | -57.5% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.09% | 422.01K | $2.44M |
| 2 | Alyeska Investment Group, L.p. | 0.08% | 416.26K | $2.41M |
| 3 | Legal & General Group PLC | 0.03% | 128.00K | $741.12K |
| 4 | Jane Street Group, LLC | 0.02% | 98.35K | $569.43K |
| 5 | Quadrature Capital Ltd | 0.01% | 41.75K | $241.73K |
| 6 | Amundi | 0.01% | 47.16K | $273.05K |
| 7 | UBS Group AG | 0.01% | 43.21K | $250.17K |
| 8 | Xtx Topco Ltd | 0.01% | 60.06K | $347.75K |
| 9 | Susquehanna International Group, LLP | - | 23.13K | $133.92K |
| 10 | Squarepoint Ops LLC | - | 22.04K | $127.59K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RGC
RGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Securities Lawsuit - Contact Levi & Korsinsky - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxNTUJGUzJUSFZGamlWOU5aQU5kek1DRlN5U2piQ3BCa3J3cm13eTBfakY5MmNtMWRLSll0cWJxRWdjR2xrajV5bEx1Y0tBNDdyYk02UmVzX00zSEphZ3QyZ1V1VEhmdEJvTWxFQVdMak1IYnhSVmphYWMzcE84RnU1cEZGZTVCTmo1NXNfcE…
Regencell Bioscience Holdings (RGC): Stock Analysis Reveals Strategic Positioning In TCM Market - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPUzY4X2k1aUYwWjIwSnpZNTZfQkVlN1dxNGgxOThOUDMxTHgweWxXUEhHSWZ4UlQ2d1k3ZFRJM1h0QUNQNURMZ0ZlR0dEZlNxeUJGRmwwYk1oRDlXaFZROVdpMFJFRkNyMkEzNEl0MDZQcnM0NHVkYWlwNmlPS1V3SGtSUzVVZ0g3SGNyZF…
A Look At Regencell Bioscience Holdings (RGC) Valuation After Department Of Justice Investigation News - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPellvbWI4ZV9INWwwQ0gyVkdPbjNsTVptbnR6S28zaDFNME9WQW1kb3lfMVdVZm14OEkyNVBCSGxRdnJSREFCRDZKY3kyODc5eUJ2ZHJNRUVhdnZPOVJEUjlZUmhlRVNCS2dfdVZUN2NoOHBmY1BzZG54bmp5bW1qVU91d2NiN3FTNHdEag…
Why (RGC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOWVpWWmZpSXloZ1JvaUVTWEJ3SHdTcXZsZ1hvS1NQeXpKVUY3NVI2cXZmelc4YmJaaG82TEJxbGNNaHgtWl9qMXhIUXp5TUdoVXhFcHpBYUV0eEV0a3BlcGZ3TFZuV1dmTS1iTkE5eHlnYlc3eHZpS1Z1WHZxRnd4bXhNcjBab1hqVTFjU1…
Director at RGC Resources (RGCO) gets stock award, bringing holdings to 14,989.906 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNaDd5czV2Q1JYbTRzTjlMTHo4T2RwTndYanFxYnZTcmZrU1UyTFFmaDcza0ZvTnZqcmVTU00yeE9idDRoU1lJaFNMcWpzaE9hdnNOelBFTFROeTlZc2ttLVg0RzJNLTd1eHQxenlwT0dTYkFNY1JfZUdsSzIxNU4xUi01LTJxWVY1NzNSaD…
Why Is RGC Stock Soaring Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQRGJzVjktTHZ1WUE5NFU0WUdZN2dIZVB0NE5vck9vZUJpQmxvc2E2c3RIY2hMUkpSQlA1eXhRcWttdVZfYl82ZzREb0FqekVkbW5iWkhsQXpJTGlLRGlpU0R2VjR3Zlp0VlliX1l4VkZ1ekI4ZUloVDY3a2MyU3dJbWhNTHI4ZzN0NV9HRW…
RGC — Frequently Asked Questions
What is the current share price of Regencell Bioscience Holdings Limited (RGC)?
As of 2026-09-19 21:16 PDT, Regencell Bioscience Holdings Limited (RGC) trades at $6.82 on NasdaqCM. Its 52-week range is $4.78 to $52.88.
What is the market capitalisation of RGC?
Regencell Bioscience Holdings Limited (RGC) has a market capitalisation of $3.37B on NasdaqCM.
What is the P/E ratio of RGC?
RGC trades at a trailing price-to-earnings (P/E) ratio of -682.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2,895.00.
Is RGC a good stock to buy?
This page provides a data-driven analysis of Regencell Bioscience Holdings Limited (RGC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.